Bolt Biotherapeutics, Inc. announced that it will present a poster with new preclinical data for BDC-3042, a Dectin-2-targeting agonistic antibody, at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2023. The conference is being held at the Orange County Convention Center in Orlando, Fla. from April 14-19, 2023.

Details about the presentation can be found below and on the AACR website. Additionally, a copy of the poster will be available on the Publications page of the Bolt Biotherapeutics website following the conference. Title: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042; Poster Board Number: 11; Abstract Presentation Number: 2964, Presenter: Justin A. Kenkel, Ph.D.; Details: Monday, April 17, 2023, 1:30 p.m. – 5:00 p.m. EDT and Location: Orange County Convention Center, Section 24.

Key Findings from the Study: Tumor-associated macrophages (TAMs) are an abundant immune cell population in many solid tumors and play a key role in establishing the immunosuppressive tumor microenvironment that enables tumor progression. However, TAMs have the potential to be reprogrammed into immunostimulatory cells that enhance innate and adaptive anti-tumor immunity. BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. Given that Dectin-2 is over-expressed in many human cancers, BDC-3042 has broad applicability as an anti-cancer therapy.

BDC-3042 exhibits strong binding to Dectin-2-expressing primary human TAMs from a range of solid tumor types. BDC-3042 activates primary human TAMs to produce an array of pro-inflammatory cytokines and chemokines associated with anti-tumor immunity. BDC-3042 elicits activation of TAMs in mice with humanized immune systems, as evidenced by induction of key proinflammatory cytokines and chemokines in the tumor microenvironment.

BDC-3042 mediates tumor growth inhibition of MDA-MB-231 tumors in humanized mice, and combination with a PD-1 checkpoint inhibitor generally enhances efficacy.